ABILIFY ASIMTUFII and ABILIFY MAINTENA are not approved for the treatment of patients with dementia-related psychosis. Contraindication: Known hypersensitivity
ABILIFY ASIMTUFII and ABILIFY MAINTENA increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ABILIFY ASIMTUFII and ABILIFY MAINTENA are not for the treatment of people with dementia-related psychosis.
ABILIFY ASIMTUFII and ABILIFY MAINTENA increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ABILIFY ASIMTUFII and ABILIFY MAINTENA are not for the treatment of people with dementia-related psychosis.
The safety and efficacy of Abilify in the treatment of patients with psychosis associated with dementia have not been established. Abilify is not indicated for
ABILIFY, are at an increased risk of death compared to placebo. ABILIFY is not approved for the treatment of people with dementia-related psychosis (see
FDA Approved Uses. Abilify/Abilify Asimtufii/Abilify Maintena/Abilify MyCite (Aripiprazole) Parkinson disease psychosis (PO). Rexulti
Bipolar maintenance [monotherapy (Abilify, Abilify Maintena) and adjunct (Abilify)] Consider pimavanserin for dementia-related psychosis or Parkinson's
ABILIFY ASIMTUFII and ABILIFY MAINTENA are not for the treatment of people with dementia-related psychosis. Do not receive ABILIFY ASIMTUFII or ABILIFY MAINTENA
memory loss (dementia). Abilify Asimtufii is not for the treatment of people with dementia-related psychosis. Abilify Asimtufii and other
Comments